Two CLEAR Outcomes Study Late-Breakers Accepted at European Society of Cardiology (ESC) Congress 2023
August 11, 2023 08:00 ET
|
Esperion Therapeutics, Inc.
ANN ARBOR, Mich., Aug. 11, 2023 (GLOBE NEWSWIRE) -- Esperion (NASDAQ: ESPR) today announced two oral presentations to take place in the Late-Breaking Science Session entitled “Clinical trial updates...
Esperion Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
August 08, 2023 16:15 ET
|
Esperion Therapeutics, Inc.
ANN ARBOR, Mich., Aug. 08, 2023 (GLOBE NEWSWIRE) -- Esperion (NASDAQ: ESPR) today announced that, on August 8, 2023, the Company granted five new employees 14,000 restricted stock units (RSUs) under...
Esperion Reports Second Quarter 2023 Financial Results
August 01, 2023 06:00 ET
|
Esperion Therapeutics, Inc.
– Q2 U.S. Net Product Revenue Grew 49% Y/Y to $20.3 Million – – Q2 Retail Prescription Equivalents Grew 26% Y/Y; Q2 New to Brand Prescriptions Grew 28% Q/Q – – Submitted Applications for Expanded...
Esperion to Participate in BTIG Virtual Biotechnology Conference 2023
July 24, 2023 08:00 ET
|
Esperion Therapeutics, Inc.
ANN ARBOR, Mich., July 24, 2023 (GLOBE NEWSWIRE) -- Esperion (NASDAQ: ESPR) today announced its participation in the BTIG Virtual Biotechnology Conference 2023. Ben Halladay, Chief Financial...
Esperion to Report Second Quarter 2023 Financial Results on August 1
July 17, 2023 06:00 ET
|
Esperion Therapeutics, Inc.
ANN ARBOR, Mich., July 17, 2023 (GLOBE NEWSWIRE) -- Esperion (NASDAQ: ESPR), today announced it will report second quarter 2023 financial results before the market opens on Tuesday, August 1, 2023. ...
Esperion to Present Additional Data from the CLEAR Outcomes Study on CVD Prevention at the American Society for Preventive Cardiology (ASPC) Congress 2023
July 07, 2023 08:00 ET
|
Esperion Therapeutics, Inc.
ANN ARBOR, Mich., July 07, 2023 (GLOBE NEWSWIRE) -- Esperion (NASDAQ: ESPR) today announced the presentation of a key abstract at the 2023 ASPC Congress on CVD Prevention taking place on July 21-23,...
Esperion Announces Submission of Application for Expanded Indication with the European Medicines Agency (EMA) for NILEMDO® (bempedoic acid) Tablet and NUSTENDI® (bempedoic acid and ezetimibe) Tablet
June 28, 2023 08:00 ET
|
Esperion Therapeutics, Inc.
– Seeking inclusion of CV risk reduction indications in Europe – – Anticipated approvals in Europe in the first half of 2024 – ANN ARBOR, Mich., June 28, 2023 (GLOBE NEWSWIRE) -- Esperion...
Esperion Presents Results from CLEAR Outcomes Primary Prevention Analysis at 83rd American Diabetes Association Scientific Sessions
June 24, 2023 14:30 ET
|
Esperion Therapeutics, Inc.
– 30% risk reduction of MACE-4 composite of death from cardiovascular causes, and >25% risk reduction across four key secondary endpoints in primary prevention population, including 27% reduction...
Esperion Presents Results from New Analysis on Cardiovascular Benefits with Bempedoic Acid Treatment at ENDO 2023
June 15, 2023 14:30 ET
|
Esperion Therapeutics, Inc.
ANN ARBOR, Mich., June 15, 2023 (GLOBE NEWSWIRE) -- Esperion (NASDAQ: ESPR) today presented results from an analysis comparing the cardiovascular risk reduction benefits of bempedoic acid treatment...
Esperion to Present New Key Science at the American Diabetes Association’s 83rd Scientific Sessions 2023
June 08, 2023 08:00 ET
|
Esperion Therapeutics, Inc.
ANN ARBOR, Mich., June 08, 2023 (GLOBE NEWSWIRE) -- Esperion (NASDAQ: ESPR) today announced the presentation of key late breaking sessions at the American Diabetes Association’s 83rd Scientific...